Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 16/20 | 0.50 |
| ▸ | PPARG | P37231 | 13/20 | 0.50 |
| ▸ | PPARD | Q03181 | 13/20 | 0.50 |
| ▸ | PPARA | Q07869 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16123797 | 1.00 | FFAR1 (0.50) | FFAR1PPARGPPARDPPARA | |
| SCHEMBL18526217 | 1.00 | FFAR1 (0.50) | FFAR1PPARGPPARDPPARA | |
| SCHEMBL10011429 | 0.90 | PPARD (0.62) | FFAR1PPARGPPARDPPARA | |
| SCHEMBL2691621 | 0.84 | PPARD (0.54) | FFAR1PPARGPPARDPPARA | |
| SCHEMBL29046597 | 0.83 | PPARD (0.48) | FFAR1PPARGPPARDPPARA | |
| SCHEMBL29046573 | 0.83 | PPARD (0.48) | FFAR1PPARGPPARDPPARA | |
| SCHEMBL16123779 | 0.82 | FFAR1 (0.70) | FFAR1 | |
| SCHEMBL15287408 | 0.79 | FFAR1 (0.53) | FFAR1 | |
| SCHEMBL13110373 | 0.78 | FFAR1 (0.62) | FFAR1PPARGPPARDPPARA | |
| SCHEMBL21178299 | 0.78 | PPARG (0.38) | FFAR1PPARGPPARDPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116547270-A | 4- (2-fluoro-4-methoxy-5-3- (((1-methylcyclobutyl) methyl) carbamoyl) bicyclo [2.2.1] hept-2-yl) carbamoyl) phenoxy) -1-methylcyclohexane-1-carboxylic acid derivatives and similar compounds as RXFP1 modulators for the treatment of heart failure | 阿斯利康(瑞典)有限公司 | 2023-08-04 | — | — | CN | disclosed |
| US-9783522-B2 | 2-amino-pyridine and 2-amino-pyrimidine derivatives and medicinal use thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2017-10-10 | — | — | US | disclosed |
| US-20170044133-A1 | NOVEL 2-AMINO-PYRIDINE AND 2-AMINO-PYRIMIDINE DERIVATIVES AND MEDICINAL USE THEREOF | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2017-02-16 | — | — | US | disclosed |
| US-8952185-B2 | Production method of optically active dihydrobenzofuran derivative | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170044133-A1 | NOVEL 2-AMINO-PYRIDINE AND 2-AMINO-PYRIMIDINE DERIVATIVES AND MEDICINAL USE THEREOF | ENPP2, ATXN2, ATXN2L | FFAR1 4612/4885PPARG 4069/4885PPARD 4139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.